highly effect attend dose schedule good regimen drug research develop combine chemotherapy strategy cancer therapy value antitumour effect dihydroberberin combine sunitinib dc human normal cell lung line oclc ncia vitro vivo show synergy provider colony format transplant tumour growth suggest increase density carcinoma studi india downregul phosphorus jk p nfκb cell tumour suppress iκb cox express admit reduce secret proinflammatori cytokine interleukin il inhibit active like contribute factor downregul consist result genomewid microarray analysis found induce cycle signal molecule known affect chang turn led collect find highlight potent molecular meghan chemotherapeut active suggest efficacy 